Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis
Top Cited Papers
Open Access
- 29 September 2008
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (10) , 3063-3070
- https://doi.org/10.1002/art.23901
Abstract
Objective To evaluate the effect of infliximab on progression of structural damage over 2 years in patients with ankylosing spondylitis (AS). Methods In the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT), a randomized, double‐blind, placebo‐controlled trial of the efficacy of infliximab compared with placebo, 279 patients with active AS received either placebo through week 24 and then infliximab 5 mg/kg from week 24 through week 96 (n = 78) or infliximab 5 mg/kg from baseline through week 96, administered every 6 weeks after a loading dose (n = 201; these patients were the focus of the radiographic analyses). Radiographic findings in patients from the ASSERT trial were indistinguishable from those in a historical control cohort of patients who had no prior use of anti–tumor necrosis factor agents (from the Outcome in Ankylosing Spondylitis International Study [OASIS] database; n = 192). Radiographic progression of structural damage from baseline to the 2‐year followup was scored using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). All images were scored in one batch. Results Median changes in the mSASSS from baseline to year 2 were 0.0 for both the OASIS and the ASSERT cohorts (P = 0.541). Mean changes in the mSASSS were also similar between the OASIS and ASSERT cohorts (mean ± SD change over 2 years 1.0 ± 3.2 and 0.9 ± 2.6, respectively). In addition, results from sensitivity analyses did not show a statistically significant difference in the mSASSS between the OASIS and ASSERT cohorts. Conclusion AS patients who received infliximab from baseline through week 96 did not show a statistically significant difference in inhibition of structural damage progression at year 2, as assessed using the mSASSS scoring system, when compared with radiographic data from the historical control OASIS cohort. Improvements in clinical outcomes and spinal inflammation have been previously demonstrated with the use of infliximab therapy.Keywords
This publication has 18 references indexed in Scilit:
- Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF- antibody infliximabRheumatology, 2007
- Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?Annals of the Rheumatic Diseases, 2007
- Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2006
- Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging dataArthritis Care & Research, 2005
- Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximabRheumatology, 2005
- How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured?Arthritis & Rheumatism, 2005
- Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)Arthritis & Rheumatism, 2005
- Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading orderAnnals of the Rheumatic Diseases, 2004
- The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: A longitudinal analysisArthritis & Rheumatism, 2004
- Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trialArthritis & Rheumatism, 2003